Clinical Trial Update: Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). [Phase 3]

View source ↗

Summary

Phase 3 trial assessing pembrolizumab with paclitaxel, with or without bevacizumab, for platinum-resistant recurrent ovarian cancer; results posted 2026-03-09 a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Neoplasms
• Ovarian Cancer
• Ovarian Epithelial Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Cancer, Carcinoma, Ovarian Epithelial | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-09